Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Study finds wearable monitors effective in diagnosing atrial fibrillation September 1, 2024 New study shows dramatic health benefits of quitting smoking February 9, 2024 WHO applauds Guinea’s success in eradicating human African trypanosomiasis January 30, 2025